ImmunityBio, Inc. (IBRX)
IBRX Stock Price Chart
Explore ImmunityBio, Inc. interactive price chart. Choose custom timeframes to analyze IBRX price movements and trends.
IBRX Company Profile
Discover essential business fundamentals and corporate details for ImmunityBio, Inc. (IBRX) to support your stock research and investment decisions.
Sector
Healthcare
Industry
Biotechnology
IPO Date
28 Jul 2015
Employees
671.00
Website
https://immunitybio.comCEO
Richard Gerald Adcock
Description
ImmunityBio, Inc., a clinical-stage biotechnology company, develops therapies and vaccines to treat cancers and infectious diseases. It offers immunotherapy and cell therapy platforms, including antibody cytokine fusion proteins, synthetic immunomodulators, vaccine technologies, natural killer cells, and adaptive (T cell) immune systems. The company also develops therapeutic agents, which are in Phase II or III clinical trial for the treatment of liquid and solid tumors, including bladder, pancreatic, and lung cancers, as well as pathogens as SARS-CoV-2 and HIV. It has collaboration agreements with National Cancer Institute, National Institute of Deafness and Communication Disorders, and Amyris, Inc.; and license agreements with CytRx Corporation, EnGeneIC Pty Limited, GlobeImmune, Inc., and Infectious Disease Research Institute, Sanford Health, Shenzhen Beike Biotechnology Co. Ltd., Sorrento Therapeutics, Inc., and Viracta Therapeutics, Inc. The company was founded in 2014 and is based in San Diego, California.
IBRX Financial Timeline
Browse a chronological timeline of ImmunityBio, Inc. corporate events including earnings releases, dividend announcements, and stock splits.
Upcoming earnings on 11 May 2026
Upcoming earnings on 11 Nov 2025
EPS estimate is -$0.10.
Earnings released on 5 Aug 2025
EPS came in at -$0.10 matching the estimated -$0.10, while revenue for the quarter reached $26.43M , missing expectations by -17.12%.
Earnings released on 12 May 2025
EPS came in at -$0.15 falling short of the estimated -$0.12 by -25.00%, while revenue for the quarter reached $16.52M , missing expectations by -0.50%.
Earnings released on 3 Mar 2025
EPS came in at -$0.15 surpassing the estimated -$0.26 by +42.31%, while revenue for the quarter reached $7.55M , missing expectations by -21.54%.
Earnings released on 12 Nov 2024
EPS came in at -$0.14 surpassing the estimated -$0.18 by +22.22%, while revenue for the quarter reached $6.11M , missing expectations by -32.69%.
Earnings released on 12 Aug 2024
EPS came in at -$0.20 falling short of the estimated -$0.17 by -17.65%, while revenue for the quarter reached $1.05M , missing expectations by -58.45%.
Earnings released on 9 May 2024
EPS came in at -$0.20 falling short of the estimated -$0.16 by -25.00%, while revenue for the quarter reached $40.00K , beating expectations by +100.00%.
Earnings released on 19 Mar 2024
EPS came in at -$0.19 falling short of the estimated -$0.18 by -5.56%, while revenue for the quarter reached $139.00K , beating expectations by +595.00%.
Earnings released on 8 Nov 2023
EPS came in at -$0.19 surpassing the estimated -$0.27 by +29.63%, while revenue for the quarter reached $82.00K , beating expectations by +310.00%.
Earnings released on 8 Aug 2023
EPS came in at -$0.28 falling short of the estimated -$0.26 by -7.69%, while revenue for the quarter reached $41.00K , missing expectations by -88.61%.
Earnings released on 11 May 2023
EPS came in at -$0.27 matching the estimated -$0.27, while revenue for the quarter reached $360.00K , meeting expectations.
Earnings released on 1 Mar 2023
EPS came in at -$0.27 falling short of the estimated -$0.22 by -22.73%, while revenue for the quarter reached $73.00K , beating expectations by +192.00%.
Earnings released on 9 Nov 2022
EPS came in at -$0.28 falling short of the estimated -$0.23 by -21.74%, while revenue for the quarter reached $118.00K , meeting expectations.
Earnings released on 8 Aug 2022
EPS came in at -$0.24 matching the estimated -$0.24, while revenue for the quarter reached $35.00K , beating expectations by +40.00%.
Earnings released on 10 May 2022
EPS came in at -$0.26 falling short of the estimated -$0.22 by -18.18%, while revenue for the quarter reached $14.00K , missing expectations by -44.00%.
Earnings released on 2 Mar 2022
EPS came in at -$0.23 falling short of the estimated -$0.21 by -9.52%, while revenue for the quarter reached $390.00K , beating expectations by +1.46K%.
Earnings released on 12 Nov 2021
EPS came in at -$0.22 falling short of the estimated -$0.20 by -10.00%, while revenue for the quarter reached $66.00K , beating expectations by +230.00%.
Earnings released on 12 Aug 2021
EPS came in at -$0.23 falling short of the estimated -$0.12 by -91.67%, while revenue for the quarter reached $339.00K , beating expectations by +43.66%.
Earnings released on 14 May 2021
EPS came in at -$0.21 surpassing the estimated -$0.41 by +48.78%, while revenue for the quarter reached $139.00K , missing expectations by -25.32%.
Earnings released on 4 Mar 2021
EPS came in at -$0.30 falling short of the estimated -$0.18 by -66.67%, while revenue for the quarter reached -$147.00K .
Earnings released on 9 Nov 2020
EPS came in at -$0.20 falling short of the estimated -$0.18 by -11.11%, while revenue for the quarter reached $151.00K .
IBRX Stock Performance
Access detailed IBRX performance analysis with candlestick charts, real‑time intraday data and historical financial metrics for comprehensive insights.
Explore Related Stocks
Compare companies within the same sector by viewing performance, key financials, and market trends. Select a symbol to access the full profile.